Table 1.

Clinical Characteristics and Allo-BMT Outcome

Patient Diagnosis*Conditioning†GVHD‡GVHD Prophylaxis1-153IVIG1-155Infections1-154Current Status
AcuteChronic
I# 
 UPN 272  MDS(RAEBt) AraC/Cy/TBI12 gr I  L  MTX/Cam  + H parainfluenzae, VZV  Relapse, alive in remission  
 UPN 273  MDS(RAEB) AraC/Cy/TBI12 No  —  MTX/Cam/CsA −  EBV  Died, infection (BLPD)  
 UPN 279 MDS(RAEBt)  AraC/Cy/TBI12 No  No  MTX/Cam +  S epidermidis Alive and well  
II 
 UPN 298  JCML  Cy/TBI7.5 gr I  E MTX/CsA/Cam  +  CMV, VZV  Alive  
 UPN 301 CML(Ph+, CP)  AraC/Bu/Cy  No  No MTX/CsA/Cam  +  —  Alive and well  
 UPN 329 JCML  Bu/Cy200 gr I  L  MTX/CsA  − CMV, RSV  Died, relapse  
III  
 UPN 274  ALL II VP16/Cy/TBI7.5 No  No  MTX/CsA  + P aeruginosa, A fumigatus Died, relapse  
 UPN 275  AML II  AraC/Cy/TBI8 No  No  MTX/CsA −  —  Alive and well  
 UPN 276  AML I AraC/Cy/TBI12 No  No  MTX/CsA  +  HSV, VZV  Alive and well  
 UPN 285  ALL II VP16/Cy/TBI7.5 gr I  No  MTX/CsA  + VZV  Alive and well  
 UPN 291  ALL II VP16/Cy/TBI12 No  No  MTX/CsA  +  — Alive and well  
 UPN 296  ALL II VP16/Cy/TBI12 gr I  L  MTX  +  S epidermidis, VZV  Alive and well 
Patient Diagnosis*Conditioning†GVHD‡GVHD Prophylaxis1-153IVIG1-155Infections1-154Current Status
AcuteChronic
I# 
 UPN 272  MDS(RAEBt) AraC/Cy/TBI12 gr I  L  MTX/Cam  + H parainfluenzae, VZV  Relapse, alive in remission  
 UPN 273  MDS(RAEB) AraC/Cy/TBI12 No  —  MTX/Cam/CsA −  EBV  Died, infection (BLPD)  
 UPN 279 MDS(RAEBt)  AraC/Cy/TBI12 No  No  MTX/Cam +  S epidermidis Alive and well  
II 
 UPN 298  JCML  Cy/TBI7.5 gr I  E MTX/CsA/Cam  +  CMV, VZV  Alive  
 UPN 301 CML(Ph+, CP)  AraC/Bu/Cy  No  No MTX/CsA/Cam  +  —  Alive and well  
 UPN 329 JCML  Bu/Cy200 gr I  L  MTX/CsA  − CMV, RSV  Died, relapse  
III  
 UPN 274  ALL II VP16/Cy/TBI7.5 No  No  MTX/CsA  + P aeruginosa, A fumigatus Died, relapse  
 UPN 275  AML II  AraC/Cy/TBI8 No  No  MTX/CsA −  —  Alive and well  
 UPN 276  AML I AraC/Cy/TBI12 No  No  MTX/CsA  +  HSV, VZV  Alive and well  
 UPN 285  ALL II VP16/Cy/TBI7.5 gr I  No  MTX/CsA  + VZV  Alive and well  
 UPN 291  ALL II VP16/Cy/TBI12 No  No  MTX/CsA  +  — Alive and well  
 UPN 296  ALL II VP16/Cy/TBI12 gr I  L  MTX  +  S epidermidis, VZV  Alive and well 
*

Diagnosis: MDS(RAEB)/(RAEBt), myelodysplastic syndrome with refractory anemia and excess of blasts; t, in transformation; (J)CML, (juvenile) chronic myeloid leukemia; Ph+, with presence of Philadelphia chromosome; CP, in chronic phase; ALL, acute lymphoid leukemia; AML, acute myeloid leukemia in first (I) or second (II) complete remission.

†

Conditioning: AraC, total dose of 4 g/m2 cytosine arabinoside; Cy, total dose of 120 mg/kg body weight (BW) cyclophosphamide, with the exception of UPN 329 who received 200 mg/kg BW; Bu, total dose of 20 mg/kg BW busulfan; VP16, total dose of 700 mg/m2 etoposide; TBI, total body irradiation either a single dose of 7.5/8 Gy or 2 × 6 Gy.

‡

Acute GVHD with grade (gr) I-IV; chronic GVHD is either limited (L) or extensive (E).

F1-153

GVHD prophylaxis consisted of a total dose of methotrexate (MTX) at 10 mg/m2 ×3 accompanied by Campath (Cam) at 0.2 mg/kg BW ×4 and/or CsA at 2 mg/kg BW/d intravenously (day −5 to +30 followed by 6 mg/kg BW/d/os through day +180) and tapered off until discontinuation at day +280; or MTX at 10 mg/m2 ×4 followed by 10 mg/m2/wk until day +100 (UPN 296).

F1-155

Intravenous Ig, administration 1 to 3 months after allo-BMT.

F1-154

Severe infections, ie, bacteraemia, septicaemia, pneumonia (A Fumigatus), and virus reactivations/infections, occurring within the first year after BMT (onset of all infections was from 5 to 134 days post-BMT). VZV, varicella-zoster virus; EBV, Epstein-Barr virus; CMV, cytomegalovirus (pp65-antigenemia, pre-emptively treated with gancyclovir); RSV, respiratory syncytial virus; HSV, herpes simplex virus.

#Transplantation groups: I, TCD BM graft from MUD; II, unmanipulated BM graft from MUD; III, unmanipulated BM graft from HLA-identical sibling donor.

View Large